sacituzumab govitecan


( Last Updated : June 2, 2021)
Generic Name:
sacituzumab govitecan
Project Status:
Pending
Therapeutic Area:
Locally advanced or metastatic triple-negative breast cancer
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
PC0254-000

Details


Manufacturer Requested Reimbursement Criteria1:
As per the anticipated Health Canada indication, for the treatment of “adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies, including at least one prior therapy for locally advanced or metastatic disease”.
Submission Type:
Initial
Fee Schedule:
Pending
Tumour Type:
Breast
Indications:
The anticipated Health Canada indication is for the treatment of “adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies, including at least one prior therapy for locally advanced or metastatic disease”.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.